Exceptional Track Record of Creating Long Term Shareholder Value
FORWARD LOOKING STATEMENT

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Framework for Long Term Value Creation

Balance
Relevance
Global Presence
Financial Performance
Leadership in the Diverse Areas of Healthcare

**EPD**
- Leading positions in India, Russia and Latin America

**NUTRITION**
- #1 Adult Nutrition
- #1 in U.S. Pediatric Nutrition

**DIAGNOSTICS**
- Industry leader in Core Lab, Molecular and Point-of-Care
- #1 Blood Screening

**MEDICAL DEVICES**
- #1 or #2 positions in Coronary Stents, Cardiac Rhythm Management, Electrophysiology and Heart Failure
- Strong positions in Neuromodulation and Diabetes Care
Aligned with Global Trends

AGING POPULATION GLOBALLY

% of Global Population > 65 years old

<table>
<thead>
<tr>
<th>Year</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>8.5%</td>
</tr>
<tr>
<td>2030</td>
<td>12.0%</td>
</tr>
<tr>
<td>2050</td>
<td>16.7%</td>
</tr>
</tbody>
</table>

Source: U.S. Census Bureau "An Aging World"; 2015
Aligned with Global Trends

GROWTH IN EMERGING MARKETS
• Investing in healthcare
• Emerging middle class

Healthcare as a % of GDP

<table>
<thead>
<tr>
<th>Region</th>
<th>Healthcare % of GDP</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>17.5%</td>
</tr>
<tr>
<td>World Avg.</td>
<td>10.0%</td>
</tr>
<tr>
<td>Latin America</td>
<td>7.2%</td>
</tr>
<tr>
<td>China</td>
<td>5.5%</td>
</tr>
<tr>
<td>Middle East</td>
<td>5.3%</td>
</tr>
<tr>
<td>India</td>
<td>4.7%</td>
</tr>
<tr>
<td>South Asia</td>
<td>4.4%</td>
</tr>
</tbody>
</table>

Sources: The World Bank World Development Indicators
Excel Funds Emerging Markets vs. Developed Markets
Nutrition

SCIENCE-BASED NUTRITION FOR EVERY STAGE OF LIFE

• #1 Pediatric in U.S.; other geographies
• #1 Adult Nutrition globally
• Uniquely balanced across products and geographies

STRATEGIC PRIORITIES

• Build strong globally recognized brands
• Capture share with innovation
• Grow and shape markets
Branded Generic Pharmaceuticals

FOCUSED GROWTH IN EMERGING MARKETS

• 100% focused on emerging markets
• Leading positions in India, Russia and Latin America
• Delivering strong sales growth

STRATEGIC PRIORITIES

• Strengthening local presence and capabilities
• Market-specific innovation
• Building locally-relevant portfolios in key therapeutic areas
Diagnostics
INNOVATIVE SOLUTIONS TO IMPROVE CARE

• Leading platforms in Core Laboratory, Point-of-Care and Molecular diagnostics

STRATEGIC PRIORITIES

• Launch next-generation Alinity systems
• Continue to expand in priority emerging markets
• Continue to drive above-market growth in developed markets
Medical Devices
CREATING A GLOBAL LEADER

• Leading positions in cardiovascular, neuromodulation and diabetes care
• #1 or #2 in several large and high-growth cardiovascular device markets
• Industry-leading pipeline

STRATEGIC PRIORITIES
• Effectively integrate Abbott and St. Jude Medical businesses
• Capture share in large established segments
• Shape and grow emerging categories
Leading Pipeline of Customer-Focused Innovation

NUTRITION

Established Pharmaceuticals

Diagnostics

Medical Devices
• Broad and balanced portfolio

• Market-leading positions

• Global presence and scale

• Delivering innovation that creates value

• Strong financial performance